Abstract: A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises an active pharmaceutical agent having solubility not less than about 10 mg/ml, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm?2 at a solid fraction representative of the tablet.

Abstract: A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises a water-soluble salt of pramipexole, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm?2 at a solid fraction representative of the tablet.

Abstract: Diffusion layer modulated solids that include an excipient and a soluble salt of a poorly soluble, basic drug; a soluble salt of a poorly soluble, acidic drug; or a poorly soluble, non-ionizable drug are useful, for example, for improved delivery of drugs.

Abstract: A discrete solid orally deliverable pharmaceutical dosage form comprises a plurality of zones, wherein (a) at least one zone comprises an NSAID; (b) at least one zone, other than a zone comprising the NSAID, comprises HPMC having dispersed therein a prostaglandin type compound in a form of a substantially water-free solid dispersion; (c) the plurality of zones are spatially arranged such that, if there is only one NSAID-containing zone and one prostaglandin-containing zone, these zones are arranged other than as a core and mantle respectively separated by an enteric coating layer; and (d) the HPMC comprises a fraction having particle size smaller than about 53 ?m, said fraction exhibiting, upon dissolution in C02-free purified water to form a 1% weight/volume solution, a pH not lower than about 4. An assay method is also provided for selecting suitable lots of HPMC for use in preparing such a dosage form.